celecoxib has been researched along with Carcinoma, Intraductal, Noninfiltrating in 3 studies
Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.
| Excerpt | Relevance | Reference |
|---|---|---|
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 7.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 3.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Generali, D | 1 |
| Buffa, FM | 1 |
| Deb, S | 1 |
| Cummings, M | 1 |
| Reid, LE | 1 |
| Taylor, M | 1 |
| Andreis, D | 1 |
| Allevi, G | 1 |
| Ferrero, G | 1 |
| Byrne, D | 1 |
| Martinotti, M | 1 |
| Bottini, A | 1 |
| Harris, AL | 1 |
| Lakhani, SR | 1 |
| Fox, SB | 1 |
| Sauter, ER | 1 |
| Qin, W | 1 |
| Schlatter, L | 1 |
| Hewett, JE | 1 |
| Flynn, JT | 1 |
1 trial available for celecoxib and Carcinoma, Intraductal, Noninfiltrating
| Article | Year |
|---|---|
COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplas | 2014 |
2 other studies available for celecoxib and Carcinoma, Intraductal, Noninfiltrating
| Article | Year |
|---|---|
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Car | 2006 |